tegee-sol
uab „solisun baltic“, Šeimyniškių g. 9-3, lt-2000 vilnius -
deosan activate pvp plus ag215, deosan activate pvp plus, agros iodo-prev pos-ordenha, deosan hitech 2 ag214, iodine teat dip solution
diversey europe operations b.v. maarssenbroeksedijk 2 3542 dn utrecht nyderlandai - jodas - veikliosios medžiagos cas nr.: 7553-56-2, eb nr.: 231-442-4, veikliosios medžiagos pavadinimas: jodas, koncentracija: 0.3% , veiklioji - veterinarinė higiena
iodosan 30, iodosan iodat, desintec fl-jodes, rotie-sol j, disinfect jod, fink - jodophos 15, jod-reiniger sauer, tankrein extra
applied biocide gmbh, siemensstraße 42 59199 bönen vokietija - jodas - veikliosios medžiagos cas nr.: 7553-56-2, eb nr.: 231-442-4, veikliosios medžiagos pavadinimas: jodas, koncentracija: 2.4% , veiklioji - veterinarinė higiena
imatinib koanaa
koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antinavikiniai vaistai - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pacientams, kurie turi mažai arba labai mažai rizikos, pasikartojimo neturėtų gauti oksaliplatina. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. išskyrus naujai diagnozuota lėtinė fazė lml, nėra kontroliuojamų tyrimų rodo, klinikinės naudos ar padidėjo išgyvenamumas šių ligų.
livtencity
takeda pharmaceuticals international ag ireland branch - maribavir - citomegalovirusinės infekcijos - antivirusiniai vaistai sisteminiam naudojimui - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antivirusinių medžiagų.
disinfectant solution.
hypred sas, 55 boulevard jules verger, bp 10180, fr-35803 dinard cedex (prancūzija). - etanolis, etilo alkoholis - veikliosios medžiagos cas nr.: 64-17-5, eb nr.: 200-578-6, veikliosios medžiagos pavadinimas: etanolis, etilo alkoholis, koncentracija: 82.9% , veiklioji
poleposition® ir mirador® mišinys
adama - koncentruota emulsija/koncentruota suspensija - azoksistrobinas + protiokonazolas - fungicidai
tarnasol
septinta s.p.r.l. - losartano kalio druska - plėvele dengtos tabletės - 100 mg; 12,5 mg; 50 mg - losartan
tarnasol plus
septinta s.p.r.l. - losartano kalio druska/hidrochlorotiazidas - plėvele dengtos tabletės - 50 mg/12,5 mg; 100 mg/25 mg - losartan and diuretics